Keytruda-Inlyta combo under Priority Review for first-line RCC

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Feb 15, 2019 at 10:52 AM.

  1. #1 cafead, Feb 15, 2019 at 10:52 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,974
    Likes Received:
    3
    via Merck & Co. Inc. (NYSE:MRK) said FDA accepted and granted Priority Review to its sBLA for Keytruda pembrolizumab plus Inlyta axitinib as a first-line treatment for renal cell carcinoma. Its PDUFA date is June 20.

    article source
     
    Quote

Reply to Thread